Biolife Solutions Stock Today

BLFS Stock  USD 20.88  1.56  6.95%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
BioLife Solutions is selling for under 20.88 as of the 5th of April 2025; that is 6.95 percent decrease since the beginning of the trading day. The stock's lowest day price was 20.07. BioLife Solutions has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 6th of March 2025 and ending today, the 5th of April 2025. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
22nd of November 1989
Category
Healthcare
Classification
Health Care
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington. The company has 46.91 M outstanding shares of which 3.47 M shares are currently shorted by private and institutional investors with about 8.98 trading days to cover. More on BioLife Solutions

Moving against BioLife Stock

  0.6CI Cigna CorpPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

BioLife Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO and President and DirectorMichael Rice
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, SP Small-Cap 600, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors)
Average Analyst Recommendation
Debt Levels
BioLife Solutions can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioLife Solutions' financial leverage. It provides some insight into what part of BioLife Solutions' total assets is financed by creditors.
Liquidity
BioLife Solutions currently holds 25.18 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. BioLife Solutions has a current ratio of 3.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BioLife Solutions' use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

3.39 Million
BioLife Solutions (BLFS) is traded on NASDAQ Exchange in USA. It is located in 3303 Monte Villa Parkway, Bothell, WA, United States, 98021 and employs 159 people. BioLife Solutions is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 979.41 M. BioLife Solutions conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 46.91 M outstanding shares of which 3.47 M shares are currently shorted by private and institutional investors with about 8.98 trading days to cover. BioLife Solutions currently holds about 46.55 M in cash with 8.43 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09.
Check BioLife Solutions Probability Of Bankruptcy
Ownership Allocation
The majority of BioLife Solutions outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in BioLife Solutions to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in BioLife Solutions. Please pay attention to any change in the institutional holdings of BioLife Solutions as this could imply that something significant has changed or is about to change at the company.
Check BioLife Ownership Details

BioLife Stock Institutional Holders

InstituionRecorded OnShares
Ameriprise Financial Inc2024-12-31
839.1 K
Geode Capital Management, Llc2024-12-31
833.4 K
Palisade Capital Management Llc2024-12-31
833.1 K
Rockefeller Capital Management L.p.2024-12-31
821.8 K
Royce & Associates, Lp2024-12-31
777.3 K
Massachusetts Financial Services Company2024-12-31
762.9 K
Ing Investment Management Llc2024-12-31
682.6 K
Gagnon Securities Llc2024-12-31
567.2 K
Bank Of America Corp2024-12-31
541.1 K
Casdin Capital, Llc2024-12-31
8.7 M
Blackrock Inc2024-12-31
5.6 M
View BioLife Solutions Diagnostics

BioLife Solutions Historical Income Statement

At this time, BioLife Solutions' Research Development is comparatively stable compared to the past year. Non Operating Income Net Other is likely to gain to about 6 M in 2025, whereas Operating Income is likely to drop (7.5 M) in 2025. View More Fundamentals

BioLife Stock Against Markets

BioLife Solutions Corporate Management

Sarah JDChief OfficerProfile
Troy WichtermanChief OfficerProfile
Geraint PhillipsSenior OperationsProfile
Troy CPAChief OfficerProfile

Additional Tools for BioLife Stock Analysis

When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.